Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Sanofi-Aventis S.A. ADR (NQ: SNY )

49.13 -0.23 (-0.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,148,184
Open 48.84
Bid (Size) 49.13 (11)
Ask (Size) 49.86 (1)
Prev. Close 49.36
Today's Range 48.17 - 49.47
52wk Range 42.63 - 57.82
Shares Outstanding 1,250,690,553
Dividend Yield 3.87%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent. 
Via Benzinga
Sanofi (SNY) Q1 2024 Earnings Call Transcript
SNY earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial

Performance

YTD
-1.74%
-1.74%
1 Month
-1.25%
-1.25%
3 Month
-1.50%
-1.50%
6 Month
-7.88%
-7.88%
1 Year
-12.61%
-12.61%

More News

Read More
Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Drugmaker Sanofi's Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings
Via Benzinga
How Is The Market Feeling About Sanofi?
Via Benzinga
(SNY) - Analyzing Sanofi's Short Interest
Via Benzinga
SNY Stock Earnings: Sanofi Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags
Via Investor's Business Daily
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Via Benzinga
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Via Benzinga
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Via Benzinga
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years
Via Benzinga
Sanofi's Multiple Sclerosis Antibody Shows Reduction Of Disease Activity
Via Benzinga
Novo Nordisk Arms Wegovy to Be a Triple Threat
Via MarketBeat
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
Via Benzinga
Exposures Product Safety
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Via InvestorPlace
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
Via Benzinga
Why Is Auddia (AUUD) Stock Up 192% Today?
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
AIRC Stock Alert: Blackstone Is Taking Apartment Income REIT Private
Via InvestorPlace
Sanofi Layoffs 2024: What to Know About the Latest SNY Job Cuts
Via InvestorPlace
Topics Workforce
Exposures Layoff
In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
What's Going On European Pharma Giant AstraZeneca Stock On Wednesday?
Via Benzinga
Krispy Kreme-McDonald's Deal Spikes Insulin Stock Interest: 'We're About To Cash In On The Aftermath'
Via Benzinga
To the Moon and Beyond: 7 Stocks With Cosmic Potential
Via InvestorPlace
Passport to Profits: 7 Global Growth Gems to Diversify Your Holdings
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.